Continuous Glucose Monitoring Metrics and Hemoglobin A1c Relationship in Patients with Type 2 Diabetes Treated by Hemodialysis
Diabetes Technology & Therapeutics · 2024-11 · 26 (11) · 862-868
DOI: 10.1089/dia.2024.0145 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 08.11.2024. Verfasst von Rodolfo J Galindo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Renal Dialysis, Blood Glucose. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
There is a need for accurate glycemic control metrics in patients with diabetes and end-stage kidney disease (ESKD). Hence, we assessed the relationship of continuous glucose monitoring (CGM) metrics and laboratory-measured hemoglobin A1c (HbA1c) in patients with type 2 diabetes (T2D) treated by hemodialysis.
Methods
This prospective observational study included adults (age 18–80 years) with T2D (HbA1c 5%–12%), treated by hemodialysis (for at least 90 days). Participants used a Dexcom G6 Pro CGM for 10 days. Correlation analyses between CGM metrics [mean glucose, glucose management indicator (GMI), and time-in-range (TIR 70–180 mg/dL)] and HbA1c were performed.
Results
Among 59 participants (mean age was 57.7 ± 9.3 years, 58% were female, 86% were non-Hispanic blacks), the CGM mean glucose level was 188.9 ± 45 mg/dL (95% CI: 177.2, 200.7), the mean HbA1c and GMI were 7.1% ± 1.3% and 7.8% ± 1.1%, respectively (difference 0.74% ± 0.95). GMI had a strong negative correlation with TIR 70–180 mg/dL (r = −0.96). The correlation between GMI and HbA1c (r = 0.68) was moderate. Up to 29% of participants had a discordance between HbA1c and GMI of 1%.
Conclusions
In patients with diabetes and ESKD treated by hemodialysis, the GMI has a strong correlation with TIR, while HbA1c underestimated the average glucose and GMI. Given the limitations of HbA1c in this population, GMI or mean glucose and TIR may be considered as more appropriate glucose control markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia, USA.
- Division of Nephrology, Kidney Research Institute, and Institute of Translational Health Sciences, University of Washington, Seattle, Washington, USA.
- Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington, USA.
- International Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota, USA.
- Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Rodolfo J Galindo, Richard M Bergenstal
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- NCATS NIH HHS
- NIMHD NIH HHS
- NIAID NIH HHS
Zitieren
APA
Galindo, R. J., Moazzami, B., Tuttle, K. R., Bergenstal, R. M., Peng, L., & Umpierrez, G. E. (2024). Continuous Glucose Monitoring Metrics and Hemoglobin A1c Relationship in Patients with Type 2 Diabetes Treated by Hemodialysis. Diabetes Technology & Therapeutics, 26(11), 862-868. https://doi.org/10.1089/dia.2024.0145
Vancouver
Galindo RJ, Moazzami B, Tuttle KR, Bergenstal RM, Peng L, Umpierrez GE. Continuous Glucose Monitoring Metrics and Hemoglobin A1c Relationship in Patients with Type 2 Diabetes Treated by Hemodialysis. Diabetes Technology & Therapeutics. 2024;26(11):862-868. doi:10.1089/dia.2024.0145
BibTeX
@article{Galindo2024,
author = {Galindo, Rodolfo J and Moazzami, Bobak and Tuttle, Katherine R and Bergenstal, Richard M and Peng, Limin and Umpierrez, Guillermo E},
title = {Continuous Glucose Monitoring Metrics and Hemoglobin A1c Relationship in Patients with Type 2 Diabetes Treated by Hemodialysis},
journal = {Diabetes Technology & Therapeutics},
year = {2024},
volume = {26},
number = {11},
pages = {862--868},
doi = {10.1089/dia.2024.0145}
}
EUVIMED